BioNTech SEBNTXEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Revenue
$187.6M
Gross Profit
$183.5M
Operating Profit
$-507.2M
Net Profit
N/A
Gross Margin
97.8%
Operating Margin
-270.4%
Net Margin
N/A
YoY Growth
N/A
Financial Flow
BioNTech SE Q1 2024 Financial Summary
BioNTech SE reported revenue of $187.6M for Q1 2024, with a net profit of N/A (N/A margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $187.6M |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | -270.4% |
| Report Period | Q1 2024 |
BioNTech SE Quarterly Revenue & Net Profit History
BioNTech SE results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 2025 | $1.5B | — | $-28.7M | -1.9% |
| Q2 2025 | $260.8M | — | $-386.6M | -148.2% |
| Q1 2025 | $182.8M | — | $-415.8M | -227.5% |
| Q3 2024 | $1.2B | — | $198.1M | 15.9% |
| Q2 2024 | $128.7M | — | N/A | N/A |
| Q1 2024 | $187.6M | — | N/A | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $187.6M | $128.7M | $1.24B | $182.8M | $260.8M | $1.52B |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Flow
No data available for this period